Skip to main content
. 2017 Jun 7;8(32):53288–53301. doi: 10.18632/oncotarget.18395

Figure 7. ApoTox-Glo assay of HN13 and HCB289 cell lines transfected with AKT1 siRNA and exposed to cetuximab (CTX) (250 μg/mL) afatinib (AFA) or allitinib (AST) 1 μM, for 24 hours.

Figure 7

Viability, cytotocity and caspase 3/7 activation of HN13 (A) and HCB289 (B).